Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Mallinckrodt
AstraZeneca
Medtronic
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,247,631

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,247,631
Title:Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.
Inventor(s): Laughlin; Mark A. (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/430,370
Patent Claims:1. A method of treating patients co-infected with [HIV-1] Human Immunodeficiency Virus-1 ("HIV-1") and [HCV] Hepatitis C Virus("HCV") which comprises administering a therapeutically effective amount of pegylated interferon-alfa in association with a therapeutically effective amount of ribavirin and a therapeutically effective amount of [HAART] Highly Active Antiretroviral Therapy and a therapeutically effective amount of a CCR5 antagonist represented by the structural formula I or II or III or IV: ##STR00060## or a pharmaceutically acceptable salt of I or II or II or IV; sufficient to lower HIV-1-RNA and HCV-RNA levels; wherein in the CCR5 antagonist compounds represented by structural formula I: ##STR00061## X is --C(R.sup.13).sub.2--, --C(R.sup.13)(R.sup.19)--, --C(O)--, --O--, --NH--, --N((C.sub.1-C.sub.6)alkyl)-, ##STR00062## R is R.sup.6-phenyl, R.sup.6-pyridyl, R.sup.6-thiophenyl or R.sup.6-naphthyl; R.sup.1 is hydrogen, (C.sub.1-C.sub.6 ) alkyl or (C.sub.2-C.sub.6)alkenyl; R.sup.2 is R.sup.7, R.sup.8, R.sup.9-phenyl; R.sup.7, R.sup.8, R.sup.9-substituted 6-membered heteroaryl; R.sup.7, R.sup.8, R.sup.9-substituted 6-membered heteroaryl N-oxide; R.sup.10, R.sup.11-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl ##STR00063## R.sup.3 is R.sup.6-phenyl, R.sup.6-heteroaryl or R.sup.6-naphthyl; R.sup.4 is hydrogen, (C.sub.1-C.sub.6) alkyl fluoro-(C.sub.1-C.sub.6 ) alkyl, cyclopropylmethyl, --CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2--O--(C.sub.1-C.sub.6 )alkyl, --CH.sub.2C(O)--O--(C.sub.1-C.sub.6)alkyl, --CH.sub.2C(O)NH.sub.2, --CH.sub.2C(O)--NH(C.sub.1-C.sub.6)alkyl or --CH.sub.2C(O)--N((C.sub.1-C.sub.6)alkyl).sub.2; R.sup.5 and R.sup.11 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl; R.sup.6 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, (C.sub.1-C.sub.6) alkyl, C.sub.1-C.sub.6)alkoxy, --CF.sub.3, CF.sub.3O--, CH.sub.3C(O)--, --CN, CH.sub.3SO.sub.2--, CF.sub.3SO.sub.2--, R.sup.14-phenyl, R.sup.14-benzyl, CH.sub.3C(.dbd.NOCH.sub.3)--, CH.sub.3C(.dbd.NOCH.sub.2CH.sub.3)--, ##STR00064## --NH.sub.2, --NHCOCF.sub.3, --NHCONH(C.sub.1-C.sub.6 alkyl), --NHCO(C.sub.1-C.sub.6 alkyl), --NHSO.sub.2(C.sub.1 -C.sub.6 alkyl), 5-membered heteroaryland ##STR00065## wherein X.sup.b is --O--, --NH--or --N(CH.sub.3)--; R.sup.7 and R.sup.8 are independently selected from the group consisting of (C.sub.1-C.sub.6)alkyl, halogen, --NR.sup.20R.sup.21, --OH, --CF.sub.3, --OCH.sub.3, --O-acyl, and --OCF.sub.3; R.sup.9 is R.sup.7, hydrogen, phenyl, --NO.sub.2, --CN, --CH.sub.2F, --CHF.sub.2, --CHO, --CH.dbd.NOR.sup.20, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, --N(R.sup.20)CONR.sup.21 R.sup.22, --NHCONH(chloro-(C.sub.1-C.sub.6)alkyl), --NHCONH((C.sub.3-C.sub.10) -cycloalkyl(C.sub.1-C.sub.6)alkyl), --NHCO(C.sub.1-C.sub.6)alkyl, --NHCOCF.sub.3, --NHSO.sub.2N((C.sub.1-C.sub.6)alkyl).sub.2, --NHSO.sub.2(C.sub.1-C.sub.6)alkyl, --N(SO.sub.2CF.sub.3).sub.2, --NHCO.sub.2(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, --SR.sup.23, --SOR.sup.23, --SO.sub.2R.sup.23, --SO.sub.2NH(C.sub.1-C.sub.6 alkyl), --OSO.sub.2(C.sub.1-C.sub.6)alkyl, --OSO.sub.2CF.sub.3, hydroxy(C.sub.1-C.sub.6)alkyl, --CON R.sup.20R.sup.21, --CON(CH.sub.2CH.sub.2--O--CH.sub.3).sub.2, --OCONH(C.sub.1-C.sub.6)alkyl, --CO.sub.2R.sup.20, Si(CH.sub.3).sub.3 or --B(OC(CH.sub.3).sub.2).sub.2; R.sup.10 is (C.sub.1-C.sub.6)alkyl, --NH.sub.2 or R.sup.12-phenyl; R.sup.12 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6) alkyl, --CF.sub.3, --CO.sub.2R.sub.20, --CN, (C.sub.1-C.sub.6)alkoxy and halogen; R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)alkyl; R.sup.17 and R.sup.18 are independently selected from the group consisting of hydrogen and C.sub.1-C.sub.6 alkyl, or R.sup.17 and R.sup.18 together are a C.sub.2-C.sub.5 alkylene group and with the carbon to which they are attached form a Spiro ring of 3 to 6 carbon atoms; R.sup.19 is R.sup.6-phenyl, R.sup.6-heteroaryl, R.sup.6-naphthyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10)cycloalky(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl; R.sup.20, R.sup.21 and R.sup.22 are independently selected from the group consisting of H and C.sub.1-C.sub.6) alkyl; and R.sup.23 is C.sub.1-C.sub.6 alkyl or phenyl; and wherein in the CCR5 antagonist compounds represented by the structural formula II: ##STR00066## or a pharmaceutically acceptable salt thereof, wherein (1) X.sup.a is --C(R.sup.13).sub.2--, --C(R.sup.13)(R.sup.19)--, --C(O)--, --O--, --NH--, --N((C.sub.1-C.sub.6)alkyl)--; ##STR00067## R.sup.a is R.sup.6a-phenyl, R.sup.6a-pyridyl, R.sup.6a-thiophenyl or R.sup.6-naphthyl; R.sup.1 is hydrogen, (C.sub.1-C.sub.6) alkyl or (C.sub.2-C.sub.6) alkenyl; R.sup.2 is R.sup.7, R.sup.8, R.sup.9-phenyl; R.sup.7, R.sup.8, R.sup.9-substituted 6-membered heteroaryl; R.sup.7, R.sup.8, R.sup.9-substituted 6-membered heteroaryl N-oxide; R.sup.10, R.sup.11-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl ##STR00068## R.sup.3 is R.sup.10-phenyl, pyridyl, pyrimidyl, pyrazinyl or thiazolyl; R.sup.4 is hydrogen, (C.sub.1-C.sub.6) alkyl, fluoro-(C.sub.1-C.sub.6) alkyl, cyclopropylmethyl, --CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2--O--(C.sub.1-C.sub.6)alkyl, --CH.sub.2C(O)--O--(C.sub.1C.sub.6)alkyl, --CH.sub.2C(O)NH.sub.2, --CH.sub.2C(O)--NH(C.sub.1-C.sub.6)alkyl or --CH.sub.2C(O)--N((C.sub.1-C.sub.6)alkyl).sub.2; R.sup.5 and R.sup.11 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl; R.sup.6a is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, --CF.sub.3, CF.sub.3O--, --CN, --CF.sub.3SO.sub.2--, R.sup.12-phenyl, --NHCOCF.sub.3, 5-membered heteroaryl and ##STR00069## wherein X.sup.b is --O--, --NH-- or --N(CH.sub.3)--; R.sup.6 is independently selected from the group consisting of R.sup.6a and CH.sub.3SO.sub.2--; R.sup.7 and R.sup.8 are independently selected from the group consisting of (C.sub.1-C.sub.6)alkyl, halogen, --NR.sup.20R.sup.21, --OH, --CF.sub.3, --OCH.sub.3, --O--acyl, and --OCF.sub.3; R.sup.9 is R.sup.7, hydrogen, phenyl, --NO.sub.2, --CN, --CH.sub.2F, --CHF.sub.2, --CHO, --CH.dbd.NOR.sup.20, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, --N(R.sup.20)CONR.sup.21R.sup.22, --NHCONH(chloro-(C.sub.1-C.sub.6)alkyl), --NHCONH((C.sub.3-C.sub.10) -cycloalkyl(C.sub.1-C.sub.6)alkyl), --NHCO(C.sub.1-C.sub.6)alkyl, --NHCOCF.sub.3, --NHSO.sub.2N((C.sub.1-C.sub.6)alkyl).sub.2, --NHSO.sub.2(C.sub.1-C.sub.6)alkyl, --N(SO.sub.2CF.sub.3).sub.2, --NHCO.sub.2(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, --SR.sup.23, --SOR.sup.23, --SO.sub.2R.sup.23, --SO.sub.2NH(C.sub.1-.sub.6 alkyl), --OSO.sub.2(C.sub.1-C.sub.6)alkyl, --OSO.sub.2CF.sub.3, hydroxy(C.sub.1-C.sub.6)alkyl, --CON R.sup.20R.sup.21, --CON(CH.sub.2CH.sub.2--O--CH.sub.3).sub.2, --OCONH(C.sub.1-C.sub.6)alkyl, --CO.sub.2R.sup.20, --Si(CH.sub.3).sub.3 or --B(OC(CH.sub.3).sub.2).sub.2; R.sup.10 is (C.sub.1-C.sub.6)alkyl, --NH.sub.2 or R.sup.12-phenyl; R.sup.12 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6) alkyl, --CF.sub.3, --CO.sub.2R.sub.20, --CN, (C.sub.1-C.sub.6)alkoxy and halogen; R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)alkyl; R.sup.17 and R.sup.18 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6) alkyl, or R.sup.17 and R.sup.18 together are a C.sub.2-C.sub.5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms; R.sup.19 is R.sup.6-phenyl, R.sup.6-heteroaryl, R.sup.6-naphthyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10)cycloalkyl(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl; R.sup.20, R.sup.21 and R.sup.22 are independently selected from the group consisting of H and C.sub.1-C.sub.6) alkyl; and R.sup.23 is C.sub.1-C.sub.6 alkyl or phenyl; or (2): X.sup.a is --C(R.sup.13)(R.sup.19)--, --C(O)--, --O--, --NH--, --N((C.sub.1-C.sub.6)alkyl)--, ##STR00070## R.sup.a is R.sup.6b-phenyl, R.sup.6b-pyridyl or R.sup.6b-thiophenyl; R.sup.4a is fluoro-C.sub.1-C.sub.6 alkyl, cyclopropylmethyl, --CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2--O--(C.sub.1-C.sub.6)alkyl, --CH.sub.2C(O)--O--(C.sub.1-C.sub.6)alkyl, --CH.sub.2C(O)NH.sub.2, --CH.sub.2C(O)--NH--(C.sub.1-C.sub.6)alkyl or --CH.sub.2C(O)--N((C.sub.1-C.sub.6)alkyl).sub.2; R.sup.6b is CH.sub.3SO.sub.2--; and R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.14, R.sup.15, R.sup.16 and R.sup.19 are as defined in II(1); and wherein in the CCR5 antagonist compounds represented by the structural formula III: ##STR00071## R is R.sup.8-phenyl, R.sup.8-pyridyl, R.sup.8-thiophenyl or R.sup.8-naphthyl; R.sup.1 is hydrogen or C.sub.1-C.sub.6 alkyl; R.sup.2 is R.sup.9, R.sup.10, R.sup.11-phenyl; R.sup.9, R.sup.10, R.sup.11-substituted 6-membered heteroaryl; R.sup.9, R.sup.10, R.sup.11-substituted 6-membered heteroaryl N-oxide; R.sup.12, R.sup.13-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl ##STR00072## R.sup.3 is hydrogen, C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkyl(C.sub.1-C.sub.6)alkyl, R.sup.8-phenyl, R.sup.8-phenyl(C.sub.1-C.sub.6)alkyl, R.sup.8-naphthyl, R.sup.8-naphthyl(C.sub.1-C.sub.6)alkyl, R.sup.8-heteroaryl or R.sup.8-heteroaryl(C.sub.1-C.sub.6)alkyl; R.sup.4, R.sup.5, R.sup.7 and R.sup.13 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl; R.sup.6 is hydrogen, C.sub.1-C.sub.6) alkyl or (C.sub.2-C.sub.6)alkenyl; R.sup.8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, (C.sub.1-C.sub.6) alkyl, C.sub.1-C.sub.6 alkoxy, --CF.sub.3, CF.sub.3O--, CH.sub.3C(O)--, --CN, CH.sub.3SO.sub.2--, CF.sub.3SO.sub.2--, R.sup.14-phenyl, R.sup.14-benzyl, CH.sub.3C(.dbd.NOCH.sub.3), CH.sub.3C(.dbd.NOCH.sub.2CH.sub.3), ##STR00073## --NH.sub.2, --NHCOCF.sub.3, --NHCONH(C.sub.1-C.sub.6 alkyl), --NHCO(C.sub.1-C.sub.6 alkyl), --NHSO.sub.2(C.sub.1-C.sub.6 alkyl), 5-membered heteroaryl and ##STR00074## wherein X.sup.b is --O--, --NH-- or --N(CH.sub.3)--; R.sup.9 and R.sup.10 are independently selected from the group consisting of (C.sub.1-C.sub.6)alkyl, halogen, --NR.sup.17R.sup.18, --OH, --CF.sub.3, OCH.sub.3, --O--acyl, --OCF.sub.3 and --Si(CH.sub.3).sub.3; R.sup.11 is R.sup.9, hydrogen, phenyl, --NO.sub.2, --CN, --CH.sub.2F, --CHF.sub.2, --CHO, --CH.dbd.NOR.sup.17, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, --N(R.sup.17)CONR.sup.18R.sup.19, --NHCONH(chloro-(C.sub.1-C.sub.6)alkyl), --NHCONH((C.sub.3-C.sub.1)cycloalkyl(C.sub.1-.sub.6)alkyl), --NHCO(C.sub.1-C.sub.6)alkyl, --NHCOCF.sub.3, --NHSO.sub.2N((C.sub.1-C.sub.6)alkyl).sub.2, --NHSO.sub.2(C.sub.1-C.sub.6)alkyl, --N(SO.sub.2CF.sub.3).sub.2, --NHCO.sub.2(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, --SR.sup.20, --SOR.sup.20, --SO.sub.2R.sup.20, --SO.sub.2NH(C.sub.1-C.sub.6 alkyl),--OSO.sub.2(C.sub.1-C.sub.6)alkyl, --OSO.sub.2CF.sub.3, hydroxy(C.sub.1-C.sub.6)alkyl, --CON R.sup.17R.sup.18, --CON(CH.sub.2CH.sub.2--O--CH.sub.3).sub.2, --OCONH(C.sub.1-C.sub.6)alkyl, --CO.sub.2R.sup.17, --Si(CH.sub.3).sub.3 or --B(OC(CH.sub.3).sub.2).sub.2; R.sup.12 is (C.sub.1-C.sub.6)alkyl, --NH.sub.2 or R.sup.14-phenyl; R.sup.14 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6) alkyl, --CF.sub.3, --CO.sub.2R.sub.17, --CN, (C.sub.1-C.sub.6)alkoxy and halogen; R.sup.15 and R.sup.16 are independently selected from the group consisting of hydrogen and C.sub.1-C.sub.6) alkyl, or R.sup.15 and R.sup.16 together are a C.sub.2-C.sub.5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms; R.sup.17, R.sup.18 and R.sup.19 are independently selected from the group consisting of H and (C.sub.1-C.sub.6) alkyl; and R.sup.20 is (C.sub.1-C.sub.6) alkyl or phenyl; and wherein in the CCR5 antagonist compounds represented by the structural formula IV: ##STR00075## or a pharmaceutically acceptable salt thereof, wherein (1) R.sup.a is R.sup.8a-phenyl, R.sup.8b-pyridyl, R.sup.8b-thiophenyl or R.sup.8-naphthyl; R.sup.1 is hydrogen or (C.sub.1-C.sub.6) alkyl; R.sup.2 is R.sup.9, R.sup.10, R.sup.11-phenyl; R.sup.9, R.sup.10, R.sup.11-substituted 6-membered heteroaryl; R.sup.9, R.sup.10, R.sup.11-substituted 6-membered heteroaryl N-oxide; R.sup.12, R.sup.13-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl, ##STR00076## R.sup.3 is hydrogen, (C.sub.1-C.sub.6) alkyl, (C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkyl(C.sub.1-C.sub.6)alkyl, R.sup.8-phenyl, R.sup.8-phenyl(C.sub.1 -C.sub.6)alkyl, R.sup.8-naphthyl, R.sup.8naphthyl(C.sub.1-C.sub.6)alkyl, R.sup.8-heteroaryl or R.sup.8-heteroaryl(C.sub.1-C.sub.6)alkyl; R.sup.4, R.sup.5, R.sup.7 and R.sup.13 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl; R.sup.6 is hydrogen, (C.sub.1-C.sub.6) alkyl or (C.sub.2-C.sub.6)alkenyl; R.sup.8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6) alkyl, C.sub.1-C.sub.6 alkoxy, --CF.sub.3, CF.sub.3O--, CH.sub.3C(O)--, --CN, CH.sub.3SO.sub.2--, CF.sub.3SO.sub.2--, R.sup.14-phenyl, R.sup.14-benzyl, CH.sub.3C(.dbd.NOOH.sub.3), CH.sub.3C(.dbd.NOCH.sub.2CH.sub.3), ##STR00077## --NH.sub.2, --NHCOOF.sub.3, --NHCONH(C.sub.1-C.sub.6 alkyl), --NHCO(C.sub.1-C.sub.6 alkyl), --NHSO.sub.2(C.sub.1-C.sub.6 alkyl), 5-membered heteroaryl and ##STR00078## wherein X.sup.b is --O--, --NH--or --N(CH.sub.3)--; R.sup.8a is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, --CF.sub.3, CF.sub.3O--, --CN, CF.sub.3SO.sub.2--, R.sup.14-phenyl, --NHCOCF.sub.3, 5-membered heteroaryl and ##STR00079## wherein X.sup.b is as defined above; R.sup.8b is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, --CF.sub.3, CF.sub.3O--, CH.sub.3C(O)--, --CN, CF.sub.3SO.sub.2--, R.sup.14-benzyl, CH.sub.3C(.dbd.NOCH.sub.3), CH.sub.3C(.dbd.NOCH.sub.2CH.sub.3), ##STR00080## --NHCOCF.sub.3, 5-membered heteroaryl and ##STR00081## wherein X.sup.b is as defined above; R.sup.9 and R.sup.10 are independently selected from the group consisting of (C.sub.1-C.sub.6)alkyl, halogen, --NR.sup.17R.sup.18, --OH, --CF.sub.3, --OCH.sub.3, --O-acyl, --OCF.sub.3 and --Si(CH.sub.3).sub.3; R.sup.11 is R.sup.9, hydrogen, phenyl, --NO.sub.2, --CN, --CH.sub.2F, --CHF.sub.2, --CHO, --CH.dbd.NOR.sup.17, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, --N(R.sup.17)CONR.sup.18R.sup.19, --NHCONH(chloro-(C.sub.1-C.sub.6)alkyl), --NHCONH((C.sub.3-C.sub.1)cycloalkyl(C.sub.1-C.sub.6)alkyl), --NHCO(C.sub.1-C.sub.6)alkyl, --NHCOCF.sub.3, --NHSO.sub.2N((C.sub.1-C.sub.6)alkyl).sub.2, --NHSO.sub.2(C.sub.1-C.sub.6)alkyl, --N(SO.sub.2CF.sub.3).sub.2, --NHCO.sub.2(C.sub.1-C.sub.6)alkyl, C.sub.3-C.sub.10 cycloalkyl, --SR.sup.20, --SOR.sup.20, SO.sub.2R.sup.20, --SO.sub.2NH(C.sub.1-C.sub.6 alkyl), --OSO.sub.2(C.sub.1-C.sub.6)alkyl, --OSO.sub.2CF.sub.3, hydroxy(C.sub.1-C.sub.6)alkyl, --CON R.sup.17R.sup.18, --CON(CH.sub.2CH.sub.2--O--CH.sub.3).sub.2, --OCONH(C.sub.1-C.sub.6)alkyl, --CO.sub.2R.sup.17, --Si(CH.sub.3).sub.3 or --B(OC(CH.sub.3).sub.2).sub.2; R.sup.12 is (C.sub.1-C.sub.6)alkyl, --NH.sub.2 or R.sup.14-phenyl; R.sup.14 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6) alkyl, --CF.sub.3, --CO.sub.2R.sub.17, --CN, (C.sub.1-C.sub.6)alkoxy and halogen; R.sup.15 and R.sup.16 are independently selected from the group consisting of hydrogen and C.sub.1-C.sub.6 alkyl, or R.sup.15 and R.sup.16 together are a C.sub.2-C.sub.5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms; R.sup.17, R.sup.18 and R.sup.19 are independently selected from the group consisting of H and C.sub.1-C.sub.6 alkyl; and R.sup.20 is (C.sub.1-C.sub.6) alkyl or phenyl; or (2) R.sup.a is R.sup.8-phenyl, R.sup.8-pyridyl or R.sup.8-thiophenyl;

R.sup.2 is fluorenyl, diphenylmethyl, ##STR00082## and R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19 and R.sup.20 are as defined in IV(1).

2. The method of claim 1, wherein the patients are treatment-naive patients.

3. The method of claim 1, wherein the patients are treatment-experienced patients.

4. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.5 to about 3.0 micrograms per kilogram in a single dose QW or divided doses BIW.

5. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.75 to about 1.5 micrograms per kilogram in a single dose QW or divided doses BIW.

6. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.5 to about 3.0 micrograms per kilogram in a single dose QW.

7. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.25 to about 1.5 micrograms per kilogram BIW.

8. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.75 to about 1.5 micrograms per kilogram in a single dose QW.

9. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is about 1.5 micrograms per kilogram in a single dose QW.

10. The method of claim 1, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2b and wherein the amount of pegylated interferon alfa-2b administered is in the range of about 0.375 to about 1.5 micrograms per kilogram BIW.

Details for Patent 7,247,631

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Schering Corporation (Kenilworth, NJ) 2019-05-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Schering Corporation (Kenilworth, NJ) 2019-05-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Schering Corporation (Kenilworth, NJ) 2019-05-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Express Scripts
Moodys
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.